Guluwa Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After washing, the area must be dried completely. A small amount of the medication should then be applied to cover each wart, ensuring that it is allowed to dry. This application should be repeated twice daily as necessary, with treatment continuing for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated on irritated skin or reddened areas due to the potential for exacerbation of the condition. Additionally, the product should not be applied to individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects. Application is also contraindicated on birthmarks, warts with hair growth, or moles, as these may present unique risks.

Warnings and Precautions

For external use only; contact with the eyes should be strictly avoided. In the event of accidental exposure to the eyes, it is imperative to rinse thoroughly with water for a minimum of 15 minutes.

Inhalation of vapors should be avoided to prevent respiratory irritation. Should ingestion occur, immediate medical assistance must be sought, or the local Poison Control Center should be contacted without delay.

If discomfort persists after use, it is advised to discontinue use and consult a healthcare professional for further evaluation.

Pregnant or breastfeeding individuals are strongly encouraged to seek advice from a healthcare provider prior to using this product to ensure safety for both the mother and child.

Side Effects

Patients using this product should be aware that it is for external use only and must avoid contact with the eyes. In the event that the product comes into contact with the eyes, it is recommended to rinse thoroughly with water for 15 minutes. Additionally, patients should avoid inhaling vapors associated with the product.

In cases where discomfort persists, it is advised that patients stop using the product and consult a healthcare professional for further guidance.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Guluwa Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, unusual behavioral changes, or any other atypical clinical manifestations.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, remain observant for potential overdose symptoms, and implement appropriate management strategies as needed.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be used on irritated skin, reddened areas, or in individuals who are diabetic or have poor blood circulation. Additionally, patients should be cautioned against using the product on birthmarks, warts with hair growth, or moles.

Patients should be instructed to stop using the product and consult a doctor if discomfort persists. Furthermore, healthcare providers should recommend that patients who are pregnant or breastfeeding consult a health professional before using the product to ensure safety.

Storage and Handling

The product is supplied in a tube that must be kept tightly closed when not in use to maintain its integrity. It should be stored at room temperature, away from direct light to protect its formulation. It is important to discard the product after opening if it is not used within the specified time frame.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a small amount to cover each wart, allowing it to dry. This application should be repeated twice daily as needed, for a duration of up to 12 weeks. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Guluwa Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)